Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of EDP-938 versus placebo in infants and young children with RSV infection
MOH_2021-07-06_010081Phase 2Active, not recruiting
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoints: Pharmacokinetics of EDP-938, Safety and tolerability of EDP-938 and 1 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2021-07-06_010081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-06_010081.